WUXI BIO News

Pharmaceutical Biotech (2269.HK): The non-COVID-19 business continues to grow rapidly while the industry gradually recovers

中泰證券Apr 7 00:00

Pharmaceutical Biotech (2269.HK) 2023 Report Review: Steady growth in revenue and profit is optimistic that the company's multiple technology platforms will drive the long-term growth of integrated CRDMO leaders

海通國際Apr 4 00:00

Pharmaceutical Biotech (02269.HK): The non-COVID-19 business maintained a high growth rate and the trend of new orders in 24 years was good

招商證券Apr 4 00:00

Pharmaceutical Biotech (02269.HK): Steady growth in the non-COVID-19 business, global production capacity layout continues to advance

開源證券Apr 2 16:06

WUXI BIOLOGICS(02269.HK):REBOUND OF THE NUMBER OF NEW PROJECTS

申万宏源研究Apr 2 14:16

Pharmaceutical Biotech (2269.HK): Performance is in line with expectations, overseas production capacity is gradually being implemented

國泰君安Apr 1 00:00

Pharmaceutical Biotech (02269.HK) 2023 Report Review: Regular Business Steady Growth, Production Capacity Construction Continues to Advance

國海證券Mar 31 00:00

Pharmaceutical Biotech (02269.HK): Steady revenue growth in 2023, business fundamentals are resilient

中金公司Mar 29 11:56

Pharmaceutical Biotech (2269.HK): Commercial production continues to expand, and the number of comprehensive projects is steadily increasing

光大證券Mar 28 19:26

WUXI BIOLOGICS(2269.HK):EXPAND OVERSEAS CAPACITY TO MITIGATE RISKS

招银国际Mar 28 13:46

Pharmaceutical Biotech (2269.HK) 2023 Annual Report Review: New global production capacity has been put into operation one after another to achieve steady growth in non-COVID-19 performance

民生證券Mar 28 11:36

Pharmaceutical Biotech (2269.HK): Performance is in line with expectations, and the number of new projects continues to be repaired

西南證券Mar 28 00:00

Damo: Maintain the target price of “gain” rating of Pharmacovigenics (02269) at HK$63.1

Zhitong FinanceMar 27 13:35

Pharmaceutical Biotech (02269.HK) Annual Report Review Report: Steady performance is in line with expectations, and the number of new projects can be expected to resume and continue to grow quarter by quarter

國盛證券Mar 27 10:41

Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy

MT NewswiresMar 1 17:05

Pharmaceutical Biotech (2269.HK): Draft US Bill Affects the Company's Continued Steady Development

國投證券Jan 31 00:00

Pharmaceutical Biotech (02269.HK): Empowering global partners to wait for the industry to bottom up

廣發證券Jan 30 18:31

Pharmaceutical Biotech (2269.HK): 132 new comprehensive projects were added in 23, and there was a sharp rebound in the number of new projects in Q4

第一上海Jan 26 14:31

Pharmaceutical Biotech (02269.HK) Company Comment: Raising the target number of new projects in 2024 can be expected to grow rapidly

國盛證券Jan 22 11:02

Pharmaceutical Biotech (02269.HK): The company raised the target number of new projects in 23 and 24, and the number of commercialized projects exceeded expectations in 23

招商證券Jan 16 09:46